Novartis, one of the world’s leading pharmaceutical innovators, announced a major strategic move: a $23 billion investment over the next five years to expand its manufacturing and research footprint across the United States. The goal? To produce 100% of its key medicines end-to-end within the US, a significant shift from its current production levels.
A Landmark Commitment to Domestic Production
The investment plan includes 10 facilities, with seven brand new sites covering both research and manufacturing. This marks one of the largest infrastructure expansions in the company’s history, bringing nearly 1,000 new jobs to Novartis and supporting an additional 4,000 jobs across the US economy.
Key Elements of the Expansion
-
Four new manufacturing facilities, three focused on biologics and one for small molecule drugs and oral solids.
-
Two new radioligand therapy (RLT) plants in Florida and Texas, bolstering Novartis’ unique position as the only company with a dedicated commercial RLT portfolio.
-
Three RLT site expansions in Indiana, New Jersey, and California.
-
A new biomedical research hub in San Diego, poised to attract top-tier scientific talent and strengthen Novartis’ US-based drug discovery capabilities.
This expansion means full domestic coverage of Novartis’ core technology platforms: small molecules, biologics, radioligand therapy, and, for the first time, siRNA therapeutics.
Strategic Timing and Market Position
The US market remains central to Novartis’ strategy, and the move comes at a time when geopolitical pressures are driving companies to reinforce domestic manufacturing. It also aligns with the US government’s push for secure and resilient medical supply chains. Notably, this investment supports the company’s 5% compound annual sales growth target through 2029, and its 40%+ core operating margin goal for 2027.